Fairvalue-Calculator Fairvalue-Calculator
EN DE

HeXun Biosciences Co (6986) Fair Value & Analysis

Healthcare · TW · Market cap 2.8B TWD

Price56.40 TWD
Fair Value48.37 TWD
Upside-14.2%
Quality95/100
Evidence: High Range 36.27 TWD – 60.46 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

HeXun Biosciences Co (6986) currently trades at 56.40 TWD, while our model-based Fair Value estimate is 48.37 TWD — implying the stock looks roughly 14.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is HeXun Biosciences Co (6986) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 48.37 TWD versus a price of 56.40 TWD — about −14% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6986?
Our 21-model fair value for HeXun Biosciences Co is 48.37 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 56.40 TWD.
What is the quality score of 6986?
HeXun Biosciences Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.